@article{96e77f0937bc4dc39dd2f0409571491e,
title = "Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy",
abstract = "Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.",
keywords = "Hepatitis D, New treatment approaches, Surrogate marker, Treatment endpoints",
author = "{Hepatitis Delta International Network (HDIN)} and Cihan Yurdaydin and Zaigham Abbas and Maria Buti and Markus Cornberg and Rafael Esteban and Ohad Etzion and Gane, {Edward J.} and Gish, {Robert G.} and Glenn, {Jeffrey S.} and Saeed Hamid and Theo Heller and Christopher Koh and Pietro Lampertico and Yoav Lurie and Michael Manns and Raymundo Parana and Mario Rizzetto and Stephan Urban and Heiner Wedemeyer and A. Wranke and {Pinheiro Borzacov}, {L. M.} and C. Lobato and S. Hamid and E. Ceausu and Dalekos, {G. N.} and A. Turcanu and Niro, {G. A.} and F. Lubna and M. Abbas and P. Ingiliz and P. Ferenci and T. Vanwolleghem and T. Hayden and N. Dashdorj and A. Motoc and S. Hardtke",
note = "Funding Information: Dr. Yurdaydin reports personal fees from GILEAD BIOPHARMA, personal fees from AbbVie BIOPHARMA, grants from EIGER BIOPHARMA, outside the submitted work. Dr. Buti. is an advisor/lecturer for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck, and Novartis. M Cornberg has received lectures and/or consultant fees from AbbVie, Bristol-Myers Squibb, Janssen, Merck/MSD, Abbott, Fujirebio and Roche; grant support from Abbott and Roche; and travel grants from Gilead Science, Bristol-Myers Squibb and Janssen. R Esteban is advisor and speaker for AbbVie, Gilead, and Merck. Dr. Glenn is employed by and owns stock in Eiger. Dr. Gane advises and is on the speakers' bureau for Janssen, Gilead, and AbbVie. Dr. Gish has had Grants/Research Support from AbbVie, Benitec Biopharma, Gilead Sciences, and Merck & Co.; consults/advises AbbVie, Akshaya Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead, Hoffman- LaRoche, Ionis Pharmaceuticals, Janssen, Merck, Nanogen and Presidio Pharmaceuticals. Dr. Manns has received grant and research support or consulting fees from Roche, BMS, Gilead, Novartis, Merck, Janssen, GSK, AbbVie. R.R.: K.V.K: Gilead, Abbott, Beckman, Boehringer Ingelheim, BMS, Conatus, Ikaria, Intercept, Janssen, Merck, Mochida, Novartis, Vertex. S.R.: Gilead, Meck, AbbVie. Dr. Lampertico serves on the speaking bureau/ and is an advisor for Alnylam, Arrowhead, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, and Roche. Dr. Urban is co-applicant and co-inventor of patents protecting myrcludex B. Dr. Wedemeyer received honoraria for speaking or consulting from Abbott, AbbVie, BMS, Boehringer Ingelheim, Eiger, Gilead Sciences, Janssen, Merck/MSD, MyrGmbH, Novartis, Novira, Roche Diagnostics, Roche, Siemens, Transgene. Research support from Abbott, BMS, Gilead Sciences, Novartis, Roche Diagnostics and Roche. Drs Abbas, Etzion, Hamid, Heller, Koh, Lurie, Parana and Rizzetto have nothing to disclose. Publisher Copyright: {\textcopyright} 2018",
year = "2019",
month = may,
doi = "10.1016/j.jhep.2018.12.022",
language = "English",
volume = "70",
pages = "1008--1015",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "5",
}
